A Selective Investment in Scandinavia
Source: http://feeds.feedburner.com/~r/etfi/~3/425955566/selective-investment-in-scandinavia.htmlPosted on Sunday, October 19th, 2008 | In Denmark, Exchange Traded Funds, Finland, Norway, Sweden
A Selective Investment in Scandinavia
As evidence of commercial interest in developing an ETF for the Nordic region, Global X Management has recently filed for such a product, based on the FTSE Nordic 30 Index. The Global X filing specifies that, “The underlying index tracks the performance of the 30 largest and most liquid companies in Sweden, Denmark, Norway, and Finland. The Adviser uses a passive or indexing approach to try to achieve the Fund’s investment objective.”
In contrast, the ETFI Nordic Region PerformIdex is a semi-active ETF proposal with quarterly rebalancing among all companies in Sweden, Denmark, Norway, and Finland with market caps over $1 billion USD. Currently, 92 companies qualify for the index with only the top 40 rated stock selected as equally-weighted, active constituents. Both the top 40 rated and all 92 companies in the ETFI Nordic PerformIdex have fared better over the past year than the closest benchmark fund on the market, iShares Sweden (EWD), and other European benchmark ETFs such as iShares S&P Europe 350 (IEV), PowerShares Europe Small-Mid Caps (PWD), and Vanguard European Stock (VGK).
Among the 10 largest Nordic companies by market cap, I am most bullish on the prospects for Novo Nordisk (NVO), which specializes in producing various types of insulin and other drugs for the growing epidemic of diabetes. Many Scandinavian companies are highly leveraged to the economy with shipping stocks such as Moller-Maersk & Torm (TRMD), energy stocks such as StatOilHydro (STO), and retailers such as Hennes & Mauritz all suffering during the current global slowdown. However, the Nordic region may offer a long-term opportunity for a turnaround play as long as the slowdown is not too long or too severe.
Last 5 posts by ETF Innovators
- Upcoming FDA Advisory Panel Meetings - March 9th, 2009
- Healthcare Investing Trends for '09 and Beyond - February 6th, 2009
- ThermoGenesis: A Stealth Stem Cell Play - January 31st, 2009
- President Obama Urges Greener Vehicles - January 26th, 2009
- Trading the Exchanges: Buying CME Group - December 26th, 2008
Denmark, Denmark, Diabetes, Energy Stocks, ETF, Exchange Traded Funds, Finland, Finland, FTSE Nordic 30, Global X Management, Hennes & Mauritz, Norway, Norway, Novo Nordisk, Scandinavia, Sweden, Sweden, USD
I am a pharmacist, freelance writer, and index developer for ETF Innovators, LLP, which creates new global equity indexes for licensing and commercialization as exchange-traded funds. I have been investing since August 1997 and freelance writing for investors since April 2007 with a focus on the healthcare sector and ETFs. I hold Doctor of Pharmacy (2003) and Bachelor of Science – Biology Major (1998) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. I am also an avid runner since 1992 and have completed 18 marathons (26.2 miles) with a personal best time of 2 hours, 54 minutes. I can be contacted by email at mikehav[at]ymail[dot]com.
My LinkedIn Profile: 
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.